Galapagos (GLPG)

Company Profile

Galapagos NV is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action.

Company profile

Ticker

GLPG, GLPGF

Exchange

NASDAQ

Website

www.glpg.com/

CEO

Paul Stoffels

Location

Belgium

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...

SEC CIK

0001421876

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

GLPG stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$52.40

Low target

$47.20

High target

$57.00

Latest filings (excl ownership)

View all

6-K

Current report (foreign)

19 Jan 23

6-K

Galapagos receives transparency notification from FMR LLC

10 Jan 23

6-K

Galapagos to present at 41th Annual J.P. Morgan Healthcare Conference

5 Jan 23

6-K

Galapagos receives transparency notification from FMR LLC

5 Jan 23

6-K

Galapagos announces changes to Executive Committee

23 Dec 22

6-K

Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care

13 Dec 22

S-8

Registration of securities for employees

12 Dec 22

6-K

Current report (foreign)

14 Nov 22

6-K

Current report (foreign)

9 Nov 22

6-K

Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results

7 Nov 22

Transcripts

GLPG

Earnings call transcript

2022 Q2

6 Aug 22

GLPG

Earnings call transcript

2022 Q1

6 May 22

GLPG

Earnings call transcript

2021 Q2

7 Aug 21

GLPG

Earnings call transcript

2020 Q3

6 Nov 20

Latest ownership filings

View all

VAN HERK INVESTMENTS B.V.

2 Nov 21

SC 13G/A

Capital International Investors

10 May 21

SC 13G/A

Capital International Investors

10 Feb 21

SC 13G

Capital International Investors

10 Feb 21

SC 13G/A

VAN HERK INVESTMENTS B.V.

Beneficial ownership report (amended)

Financial summary

Financial statements Chart GLPG financial data

Quarter (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Galapagos earnings reports.

Institutional ownership, Q3 2022

GLPG institutional ownership history Ownership history

57.7% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	82	87	-5.7%
Opened positions	20	12	+66.7%
Closed positions	25	21	+19.0%
Increased positions	24	28	-14.3%
Reduced positions	21	26	-19.2%

13F shares	Current	Prev Q	Change
Total value	3.75 bn	4.33 bn	-13.4%
Total shares	37.96 mm	38.05 mm	-0.2%
Total puts	334.00 k	65.90 k	+406.8%
Total calls	154.90 k	235.70 k	-34.3%
Total put/call ratio	2.2	0.3	+671.2%

Largest owners	Shares	Value	Change
GILD Gilead Sciences	20.63 mm	$3.20 bn	0.0%
Van Herk Investments B.V.	4.64 mm	$0.00	0.0%
FMR	3.72 mm	$158.60 mm	+4.2%
EcoR1 Capital	3.20 mm	$136.34 mm	0.0%
BLK Blackrock	481.72 k	$20.54 mm	-6.6%
Wellington Management	457.62 k	$19.51 mm	+1582.8%
Prosight Management	405.00 k	$17.27 mm	+9.8%
Finepoint Capital	379.70 k	$16.19 mm	+46.4%
Driehaus Capital Management	328.59 k	$14.01 mm	-35.7%
Hudson Bay Capital Management	322.50 k	$13.75 mm	+49.0%

Largest transactions	Shares	Bought/sold	Change
Wellington Management	457.62 k	+430.43 k	+1582.8%
Jennison Associates	0.00	-302.25 k	EXIT
JPM JPMorgan Chase & Co.	961.00	-293.47 k	-99.7%
Optiver Holding B.V.	104.11 k	-207.44 k	-66.6%
Driehaus Capital Management	328.59 k	-182.06 k	-35.7%
FMR	3.72 mm	+150.94 k	+4.2%
Jane Street	0.00	-140.23 k	EXIT
Millennium Management	161.13 k	+136.12 k	+544.3%
T. Rowe Price	129.25 k	+129.25 k	NEW
Finepoint Capital	379.70 k	+120.30 k	+46.4%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.